Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer.

Mohamed A GhonimSalome V IbbaAbdelmetalab F TarhuniYoussef ErramiHanh H LuuMatthew J DeanAli H El-BahrawyDorota WyczechowskaIlyes A BenslimaneLuis Del ValleAmir A Al-KhamiAugusto C OchoaA Hamid Boulares

Published in: Journal for immunotherapy of cancer (2021)

These results support a paradigm-shifting concept that expands the utility of PARP inhibitor and encourage testing metronomic dosing of PARP inhibitor to enhance the efficacy of checkpoint inhibitor-based immunotherapies in cancer.

Keyphrases

dna damage
dna repair
papillary thyroid
oxidative stress
cell cycle
cell proliferation
mesenchymal stem cells
lymph node metastasis